AKRO - NASDAQ
Akero Therapeutics, Inc.
$54.65
+0.0000%Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
At a Glance
Live SnapshotAkero Therapeutics, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Akero Therapeutics, Inc. Balance Sheet
AKRO • NASDAQ
| Akero Therapeutics, Inc. Balance Sheet | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|
ASSETS | ||||||||
CURRENT ASSETS | ||||||||
340.2M | 234.2M | 249.8M | 150.5M | 187.2M | 64.8M | 76M | 598K | |
402.8M | 315.8M | 101.7M | 37.8M | 81.1M | 71.6M | 0.0 | 0.0 | |
743.1M | 550M | 351.4M | 188.3M | 268.4M | 136.4M | 76M | 598K | |
0.0 | 0.0 | 3.7M | 5.3M | 3M | 1.6M | 1.2M | 40K | |
27.3M | 10M | 0.0 | 0.0 | 0.0 | 0.0 | 1.2M | 40K | |
770.4M | 560M | 355.2M | 193.6M | 271.3M | 138M | 77.1M | 638K | |
NON-CURRENT ASSETS | ||||||||
755K | 1M | 1.3M | 1.5M | 1.8M | 0.0 | 0.0 | 0.0 | |
54.8M | 19.3M | 0.0 | 0.0 | 0.0 | 0.0 | 20K | 20K | |
0.0 | 0.0 | 108K | 417K | 201K | 69K | 0.0 | 0.0 | |
55.5M | 20.3M | 1.4M | 2M | 2M | 69K | 20K | 20K | |
825.9M | 580.3M | 356.6M | 195.5M | 273.3M | 138.1M | 77.2M | 658K | |
LIABILITIES | ||||||||
CURRENT LIABILITIES | ||||||||
9M | 7M | 8M | 6.7M | 3.4M | 947K | 1.4M | 60K | |
9M | 7M | 8M | 6.7M | 3.4M | 947K | 1.4M | 60K | |
28.9M | 10.3M | 804K | 17.7M | 8.9M | 6.7M | 304K | 160K | |
631K | 522K | 325K | 205K | 294K | 85K | 0.0 | 0.0 | |
1.2M | 1.3M | 10M | 554K | 495K | 1.6M | 665K | 2K | |
39.8M | 19.1M | 19.1M | 25.1M | 13.1M | 9.4M | 2.3M | 222K | |
NON-CURRENT LIABILITIES | ||||||||
35.3M | 25M | 9.5M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
194K | 54K | 305K | 0.0 | 0.0 | 23K | 124.7M | 5M | |
36M | 25.8M | 10.9M | 1.3M | 1.5M | 23K | 124.7M | 5M | |
1.2M | 1.3M | 1.4M | 1.5M | 1.8M | 85K | 0.0 | 0.0 | |
75.8M | 45M | 30M | 26.4M | 14.6M | 9.4M | 127.1M | 5.2M | |
SHAREHOLDERS' EQUITY | ||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 124.7M | 5M | |
7K | 6K | 5K | 4K | 4K | 3K | 0.0 | 0.0 | |
1.6B | 1.1B | 748.9M | 479.4M | 468.2M | 259M | 36.6M | 0.0 | |
-826.2M | -574.1M | -422.3M | -310.3M | -209.5M | -130.3M | -86.6M | -4.6M | |
948K | 270K | 37K | -27K | -3K | -6K | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -124.7M | -5M | |
750.1M | 535.3M | 326.6M | 169.1M | 258.7M | 128.7M | -49.9M | -4.6M | |
750.1M | 535.3M | 326.6M | 169.1M | 258.7M | 128.7M | -49.9M | -4.6M | |
SUMMARY | ||||||||
825.9M | 580.3M | 356.6M | 195.5M | 273.3M | 138.1M | 77.2M | 658K | |
457.6M | 335.1M | 101.7M | 37.8M | 81.1M | 71.6M | 20K | 20K | |
36.5M | 26.3M | 10.9M | 1.5M | 1.8M | 85K | 0.0 | 0.0 | |
-303.8M | -207.9M | -238.8M | -149M | -185.4M | -64.7M | -76M | -598K | |
82,316,179 | 82,316,179 | 82,316,179 | 82,316,179 | 82,316,179 | 82,316,179 | 82,316,179 | 82,316,179 |
SEC Filings
AKRO - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2025 N/A | December 09, 2025 | December 09, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 03, 2025 | December 02, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 07, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 09, 2025 | October 08, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 29, 2025 | September 23, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 08, 2025 | June 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 08, 2025 | August 08, 2025 | 2025 | |
8-K 8-K 2025 N/A | June 04, 2025 | June 03, 2025 | 2025 | |
10-Q 10-Q 2025 Q1 Q1 | May 12, 2025 | March 31, 2025 | 2025 | |
8-K 8-K 2025 N/A | May 12, 2025 | May 12, 2025 | 2025 |
Related Guides
Continue your AKRO research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.